What is Night Eating Syndrome, and how is it different from just eating late?

Night Eating Syndrome (NES) is a distinct clinical eating pattern recognized in DSM-5 under 'Other Specified Feeding or Eating Disorder' (OSFED). The proposed diagnostic criteria (Allison 2010, International Journal of Eating Disorders) require ≥25% of daily caloric intake after the evening meal, and/or ≥2 nocturnal ingestions per week with awareness of eating, plus at least three associated features: morning anorexia, a strong urge to eat between dinner and sleep, insomnia four or more nights per week, belief that one must eat to fall or return to sleep, or depressed mood that worsens in the evening. A late chronotype or a personal preference for a 9 pm dinner is not NES. NES has to be present most days over a 3-month period, cause meaningful distress or impairment, and not be better explained by another disorder.

Is Night Eating Syndrome the same as binge eating?

No. Binge eating disorder (BED) is defined by episodes in which a person eats an objectively large amount of food in a discrete period with loss of control, and DSM-5 requires ≥1 episode per week for at least 3 months. NES is defined by the timing and pattern of intake — the calories concentrate after the evening meal and there is often awareness during nocturnal eating, without the discrete loss-of-control episode. The two conditions can co-occur, but a night-eating pattern without loss-of-control binge episodes is not BED, and a daytime binge pattern without evening hyperphagia is not NES. The differential matters because CBT-E (for BED) and CBT-NES (for NES) target different mechanisms.

Will an SSRI actually help NES?

Sertraline has the strongest RCT evidence. Allison 2018 in the American Journal of Psychiatry randomized 34 adults with NES to sertraline titrated to 200 mg/day versus placebo over 8 weeks and reported significant reductions in Night Eating Questionnaire (NEQ) scores and greater weight loss on sertraline (4.9% vs 1.8% on placebo). The response is meaningful but the trial is small; medication alone is not curative, and the standard of care pairs an SSRI with CBT-NES. Other SSRIs have not been formally tested at RCT scale for NES.

Should I skip breakfast if I know I'll eat at night?

No — skipping breakfast is one of the drivers of NES, not a fix for it. The pathophysiology described by Goel 2009 (Obesity) shows that NES is a circadian phase-delay disorder: the appetite curve shifts ~1 to 2.5 hours later than usual, so daytime hunger is blunted and evening hunger is amplified. Skipping breakfast reinforces the rebound. The single most tractable behavioral lever is a structured protein-anchored breakfast within 60 minutes of waking, which resets the daytime-intake curve and reduces evening hyperphagia over 4 to 8 weeks.

How is NES different from Sleep-Related Eating Disorder (SRED)?

Awareness. In NES, the person is awake and remembers eating; the pattern is a shifted circadian intake curve with insomnia and evening hyperphagia. In SRED, the nocturnal eating happens during a partial arousal from sleep with impaired awareness and often amnesia the next morning; it is classified as a parasomnia. SRED is frequently linked to sedative-hypnotic medications — zolpidem is a classic offender — and to restless legs syndrome and sleepwalking. If your first sign of night eating is finding wrappers in the morning you do not remember, that is SRED until proven otherwise, and it needs a sleep-medicine evaluation and often medication review.

Do I need to be treated for NES before bariatric surgery?

Yes, if you screen positive. Latner 2004 in Obesity Research showed that untreated NES before bariatric surgery predicted worse post-surgical weight-loss outcomes and re-emergence of the night-eating pattern within 1 to 2 years post-op. NES prevalence in bariatric-surgery candidates is estimated at 8 to 15 percent (Colles 2007, Runfola 2014), and pre-op screening with the NEDQ or NEQ is standard in most bariatric programs. Active untreated NES is a reason to delay surgery until a course of CBT-NES ± sertraline stabilizes the pattern, not a permanent exclusion.

Will GLP-1 medications treat my NES?

There is no RCT evidence for GLP-1s as a NES treatment as of 2026. Mechanistically, evening ghrelin blunting on semaglutide or tirzepatide may reduce nocturnal appetite in some patients, and small case series describe symptomatic improvement, but that is not the same as a treatment indication. Using a GLP-1 in place of CBT-NES and sertraline risks delaying evidence-based care. The right sequence is a behavioral-health evaluation, CBT-NES ± sertraline, and a GLP-1 considered as an adjunct in coordination with your prescriber if weight or metabolic goals warrant it.

2026-07-09 · night eating syndrome, NES, eating disorders, circadian, sertraline, CBT, weight loss · 16 min read

Written by Nora Kim

Nora Kim covers medical and surgical weight loss options, GLP-1 therapies, and evidence-based supplements. She focuses on explaining clinical research, safety considerations, and practical next steps so readers can discuss treatment choices with their care teams.

What is Night Eating Syndrome, and how is it different from just eating late?: Night Eating Syndrome (NES) is a distinct clinical eating pattern recognized in DSM-5 under 'Other Specified Feeding or Eating Disorder' (OSFED). The proposed diagnostic criteria (Allison 2010, International Journal of Eating Disorders) require ≥25% of daily caloric intake after the evening meal, and/or ≥2 nocturnal ingestions per week with awareness of eating, plus at least three associated features: morning anorexia, a strong urge to eat between dinner and sleep, insomnia four or more nights per week, belief that one must eat to fall or return to sleep, or depressed mood that worsens in the evening. A late chronotype or a personal preference for a 9 pm dinner is not NES. NES has to be present most days over a 3-month period, cause meaningful distress or impairment, and not be better explained by another disorder.
Is Night Eating Syndrome the same as binge eating?: No. Binge eating disorder (BED) is defined by episodes in which a person eats an objectively large amount of food in a discrete period with loss of control, and DSM-5 requires ≥1 episode per week for at least 3 months. NES is defined by the timing and pattern of intake — the calories concentrate after the evening meal and there is often awareness during nocturnal eating, without the discrete loss-of-control episode. The two conditions can co-occur, but a night-eating pattern without loss-of-control binge episodes is not BED, and a daytime binge pattern without evening hyperphagia is not NES. The differential matters because CBT-E (for BED) and CBT-NES (for NES) target different mechanisms.
Will an SSRI actually help NES?: Sertraline has the strongest RCT evidence. Allison 2018 in the American Journal of Psychiatry randomized 34 adults with NES to sertraline titrated to 200 mg/day versus placebo over 8 weeks and reported significant reductions in Night Eating Questionnaire (NEQ) scores and greater weight loss on sertraline (4.9% vs 1.8% on placebo). The response is meaningful but the trial is small; medication alone is not curative, and the standard of care pairs an SSRI with CBT-NES. Other SSRIs have not been formally tested at RCT scale for NES.
Should I skip breakfast if I know I'll eat at night?: No — skipping breakfast is one of the drivers of NES, not a fix for it. The pathophysiology described by Goel 2009 (Obesity) shows that NES is a circadian phase-delay disorder: the appetite curve shifts ~1 to 2.5 hours later than usual, so daytime hunger is blunted and evening hunger is amplified. Skipping breakfast reinforces the rebound. The single most tractable behavioral lever is a structured protein-anchored breakfast within 60 minutes of waking, which resets the daytime-intake curve and reduces evening hyperphagia over 4 to 8 weeks.
How is NES different from Sleep-Related Eating Disorder (SRED)?: Awareness. In NES, the person is awake and remembers eating; the pattern is a shifted circadian intake curve with insomnia and evening hyperphagia. In SRED, the nocturnal eating happens during a partial arousal from sleep with impaired awareness and often amnesia the next morning; it is classified as a parasomnia. SRED is frequently linked to sedative-hypnotic medications — zolpidem is a classic offender — and to restless legs syndrome and sleepwalking. If your first sign of night eating is finding wrappers in the morning you do not remember, that is SRED until proven otherwise, and it needs a sleep-medicine evaluation and often medication review.
Do I need to be treated for NES before bariatric surgery?: Yes, if you screen positive. Latner 2004 in Obesity Research showed that untreated NES before bariatric surgery predicted worse post-surgical weight-loss outcomes and re-emergence of the night-eating pattern within 1 to 2 years post-op. NES prevalence in bariatric-surgery candidates is estimated at 8 to 15 percent (Colles 2007, Runfola 2014), and pre-op screening with the NEDQ or NEQ is standard in most bariatric programs. Active untreated NES is a reason to delay surgery until a course of CBT-NES ± sertraline stabilizes the pattern, not a permanent exclusion.
Will GLP-1 medications treat my NES?: There is no RCT evidence for GLP-1s as a NES treatment as of 2026. Mechanistically, evening ghrelin blunting on semaglutide or tirzepatide may reduce nocturnal appetite in some patients, and small case series describe symptomatic improvement, but that is not the same as a treatment indication. Using a GLP-1 in place of CBT-NES and sertraline risks delaying evidence-based care. The right sequence is a behavioral-health evaluation, CBT-NES ± sertraline, and a GLP-1 considered as an adjunct in coordination with your prescriber if weight or metabolic goals warrant it.

Night Eating Syndrome and Weight Loss: How to Recognize the DSM-5 Pattern, Distinguish It From Snacking or Bingeing, and Actually Treat It

Quick stats

Adult general-population prevalence: ~1.5% (Rand 1997; de Zwaan 2015 review)
Obesity-treatment-seeking populations: 6–14% (Colles 2007)
Bariatric-surgery candidates: 8–15% (Runfola 2014; Colles 2007)
Comorbid mood disorder: ~50% of NES cohorts (de Zwaan 2006)
First-line pharmacology: sertraline titrated to 200 mg/day (Allison 2018 RCT)
First-line behavioral therapy: CBT-NES (Allison 2010 pilot; Berner 2011)
Crisis resources: 988 (Suicide & Crisis Lifeline), 1-800-931-2237 (NEDA helpline)

Who this is for — and not for

This guide is written for adults who suspect a real evening-hyperphagia and/or nocturnal-ingestion pattern, and who want to understand what NES is, how it differs from ordinary late-night snacking, and what treatment actually looks like. It is not a substitute for evaluation by a clinician. Screening tools like the Night Eating Diagnostic Questionnaire (NEDQ) or the 14-item Night Eating Questionnaire (NEQ) can point toward the diagnosis, but only a trained behavioral-health clinician can confirm it against DSM-5 criteria. If you are in crisis or having thoughts of self-harm, call or text 988 in the US right now, or contact the NEDA helpline at 1-800-931-2237.

If your late-night eating is occasional, planned, non-distressing, and unrelated to insomnia or mood, you are almost certainly describing a habit, not a syndrome. That belongs in the general snacking for weight loss discussion, not here.

Primer table — five patterns that get confused

Four eating patterns get confused constantly, and one row that summarizes how to tell them apart. This table is the short version; DSM-5 sits behind the diagnostic side.

Pattern	Defining feature	Awareness	Loss of control	Typical treatment
Night Eating Syndrome (NES)	≥25% of daily intake after the evening meal and/or ≥2 nocturnal ingestions/week; morning anorexia; evening/nocturnal insomnia	Awake and aware	No discrete binge episodes	CBT-NES + sertraline
Sleep-Related Eating Disorder (SRED)	Nocturnal eating during partial arousal from sleep; often amnesia; parasomnia-linked	Impaired / amnestic	Not applicable — dissociated	Sleep medicine; medication review (zolpidem)
Binge Eating Disorder (BED)	Recurrent binge episodes ≥1×/week for ≥3 months; objectively large amount in a discrete period	Fully aware	Yes, defining feature	CBT-E ± lisdexamfetamine
Late-night snacking (subclinical)	Behavioral pattern; small evening intake; no clinical criteria met	Fully aware	No	Habit change, sleep hygiene
How to tell them apart	Timing (evening for NES/late-snacking; discrete episode for BED; asleep for SRED); awareness (impaired only in SRED); control (lost only in BED); distress and impairment (present in NES, BED, SRED — absent in ordinary late snacking)	—	—	—

If you have read our binge eating disorder and weight loss guide and the description “does not quite fit” — particularly if the pattern is a slow drift of intake into the evening rather than a discrete binge episode — NES is the right place to look. If the driver feels more like affect than timing — eating in response to stress, boredom, or low mood at any hour — the closer fit is emotional eating and weight loss, which is a behavioral pattern rather than a DSM-5-defined clinical disorder.

What actually drives NES — 4 mechanisms

NES is not a willpower failure. Four mechanisms drive the pattern, and treatment targets each of them.

1. Delayed circadian food-intake phase

Goel 2009 (Obesity) is the landmark chronobiology paper. Adults with NES showed a 1.0 to 2.5 hour delay in their food-intake curve compared with matched controls, with a shifted cortisol rhythm (blunted morning peak) and delayed melatonin onset. The subjective experience — no appetite in the morning, ramping hunger through the evening, cravings at bedtime and after — is a direct read-out of a circadian misalignment. This is the core biology and the reason bright-light therapy and a structured morning breakfast are on the treatment list. For the wider chrono-appetite context, see meal timing and chrononutrition and leptin, ghrelin, and appetite hormones.

2. Skipped or minimal daytime intake → evening rebound

Because morning appetite is blunted, most people with NES eat little or nothing before mid-afternoon. That daytime deficit is a physiological setup for evening hyperphagia — hunger hormones (ghrelin) rise, satiety hormones (leptin, PYY) fall, and by 7 or 8 pm the appetite drive is disproportionate to the day’s total intake. Skipping breakfast is a driver of the loop, not a remedy for it. This is the single most tractable behavioral lever, and the reason a protein-anchored morning meal is part of step 2 of the protocol.

3. Sleep-onset insomnia and nocturnal food-cue exposure

Roughly three-quarters of NES adults report sleep-onset insomnia or frequent awakenings. Every additional awakening is an additional food-cue exposure — the kitchen is a few steps away, sleep is not restorative, and the belief “I need to eat to fall back asleep” gets reinforced episode by episode. Untreated insomnia and unstructured evenings compound the pattern independently of the underlying circadian shift.

4. Comorbid mood, anxiety, and depression

de Zwaan 2006 and multiple subsequent cohort reviews document mood-disorder comorbidity in roughly 50 percent of NES patients, with major depression the most common. Evening-specific mood worsening — a criterion in the Allison 2010 research diagnostic scheme — is part of the clinical picture. Treating the mood side alone does not resolve NES, and treating NES alone does not resolve depression; the two need coordinated care. The bidirectional link with depression and body weight sits in depression and weight loss.

What the evidence actually shows

Prevalence

Rand 1997 first estimated adult general-population prevalence at ~1.5 percent. Colles 2007 (International Journal of Obesity) reported 6 to 14 percent prevalence in obesity-treatment-seeking populations, with the higher end in bariatric-surgery candidates. Runfola 2014 (Behaviour Research and Therapy), a large clinical-sample study, reported 8 to 15 percent NES prevalence in bariatric candidates. de Zwaan 2015 synthesized the prevalence and comorbidity literature and confirmed the pattern: NES is uncommon in the general population and substantially over-represented in higher-BMI clinical populations.

Longitudinal weight trajectory

Andersen 2004 (American Journal of Clinical Nutrition) and Marshall 2004 (American Journal of Psychiatry) followed adults with and without NES over 6 years. Both studies found that NES independently predicted weight gain across the follow-up period, holding baseline BMI constant. That is why NES is not “just a habit that will resolve on its own” — the pattern is a real, prospective risk factor for weight gain and metabolic decompensation.

Circadian biology

Goel 2009 (above) is the paper to cite here. The 1.0 to 2.5 hour phase delay in food intake, cortisol, and melatonin is measurable, replicable across cohorts, and directly maps to the clinical picture. This is why a morning bright-light exposure is on the intervention list — the mechanism is a circadian phase advance, not a mood boost.

Pharmacology evidence

Allison 2018 (American Journal of Psychiatry) is the pivotal RCT. Thirty-four adults with NES were randomized to sertraline titrated to 200 mg/day or placebo over 8 weeks. Sertraline produced significant reductions in NEQ scores and greater weight loss (4.9% versus 1.8% on placebo). The trial is small but the effect size is meaningful and internally consistent. Sertraline is the SSRI with the strongest RCT evidence for NES; other SSRIs have observational support but no RCT.

CBT-NES trials

Allison 2010 (Eating Behaviors) piloted a 10-session CBT-NES protocol adapted from CBT-E and CBT for insomnia. Berner 2011 and subsequent replications reported meaningful reductions in evening-intake percentage, NEDQ scores, and depression scales at end of treatment. CBT-NES is the first-line behavioral therapy; the combination of CBT-NES plus sertraline is the best-evidence stack.

Bright-light therapy

Friedman 2002 (Journal of Clinical Psychiatry) reported the first case series showing morning bright-light exposure reduced NES symptoms in a small cohort. McCune 2015 (Journal of Nervous and Mental Disease) piloted a randomized trial of 14-day morning bright light in NES patients and reported reduced evening hyperphagia and NEQ scores. The mechanism is a circadian phase advance. Evidence is preliminary but consistent with the Goel 2009 pathophysiology.

Time course under standard treatment

Standard treatment is CBT-NES + sertraline titrated to 200 mg/day + morning bright light + structured breakfast and sleep hygiene. The trajectory below approximates the aggregate literature; individual response varies.

Time point	Evening-intake %	NEQ score	Weight	Mood
Baseline (onset)	35–45%	30–40	Baseline; trending up historically	Evening-worse mood; NEQ mood item elevated
1 month	30–35%	25–30	Stable	Sleep-onset improving; morning appetite returning
3 months	25–30%	20–25	−1 to −3%	Evening cravings less compulsive
6 months	20–25%	15–20	−3 to −5%	Mood stabilized; nocturnal awakenings rare
12 months	≤25%	10–15	−5 to −8% (Allison 2018 trajectory)	Sustained remission for most responders
2 years	≤25%, stable	≤10	Maintained; regain possible if treatment stops abruptly	Continued CBT booster or SSRI maintenance often warranted

The 5-step protocol — screening first, referral emphasized

None of these steps replace clinical evaluation. Each is a piece of the standard-of-care approach.

Step 1: Screen with the NEDQ or NEQ

The Night Eating Diagnostic Questionnaire (NEDQ) and the 14-item Night Eating Questionnaire (NEQ) are the two most-used public-domain screens. Both take five minutes to complete. A NEQ score of 25 or above is a common clinical cut-off for a positive screen; a score above 30 warrants prompt evaluation. Screening is not diagnosis — a positive screen is a reason to see a behavioral-health clinician, not a label.

Step 2: Establish a structured, protein-anchored breakfast within 60 minutes of waking

This is the single most tractable behavioral lever, and it directly targets the daytime-skip → evening-hyperphagia loop. Aim for 25 to 35 g of protein within an hour of waking — Greek yogurt, eggs, a whey shake, cottage cheese. The high-protein snacks list applies here too. Expect four to eight weeks of consistent morning intake before evening appetite noticeably decreases. Do not aim for a full “large breakfast” if morning nausea is severe — start with 10 to 15 g of protein and build up.

Step 3: Sleep hygiene fundamentals

Fixed sleep window, no phone in bed, 15 to 30 minutes of morning bright light (outdoor light within an hour of waking, or a 10,000-lux light box if outdoor exposure is not possible), consistent wake time on weekends. Untreated insomnia amplifies NES by increasing nocturnal food-cue exposure. The full protocol lives in sleep, stress, and weight management; the circadian mechanics that connect it to appetite are in meal timing and chrononutrition.

If nocturnal eating is accompanied by amnesia the next morning — finding wrappers, crumbs, or empty containers you do not remember — this is SRED, not NES, until proven otherwise. Zolpidem is the classic pharmacologic trigger and any Z-drug, benzodiazepine, or sedating antipsychotic on your medication list warrants a review with your prescriber. SRED is managed by sleep medicine, not eating-disorder care.

Step 5: Referral to an eating-disorder–informed clinician

CBT-NES is first-line; sertraline is the SSRI with the strongest RCT evidence at 200 mg/day; morning bright light is a reasonable adjunct. Do not initiate weight-loss surgery — including sleeve gastrectomy, bypass, or SADI — without first treating NES. Latner 2004 (below) showed post-surgical weight outcomes are worse when NES is untreated. If you are pursuing bariatric care, complete a course of CBT-NES first and re-screen post-op.

Treatment comparison — six options

Approach	Evidence type	What it targets	Typical response	Caveats
CBT-NES	Allison 2010 pilot; Berner 2011 replications	Behavioral loops (skipped breakfast, nocturnal insomnia, cognitions)	NEQ and evening-intake % reductions at end of treatment	Access to eating-disorder–informed CBT clinicians is the limit
Sertraline 200 mg/day	Allison 2018 RCT (n=34)	Circadian and serotonergic tone; evening mood	~5% weight loss and NEQ reduction at 8 weeks	Single small RCT; other SSRIs less studied
Bright-light therapy	Friedman 2002 case series; McCune 2015 pilot RCT	Circadian phase (advance morning)	Reduced evening hyperphagia	Preliminary; best used as adjunct to CBT-NES
Generic sleep hygiene	Broad insomnia literature	Sleep-onset and awakenings	Small NES benefit alone	Necessary but not sufficient
Generic weight-loss counseling	No NES-specific RCT	Total intake	Weak; often triggers restrict-rebound	Not appropriate as monotherapy for NES
GLP-1 monotherapy (no NES-specific care)	No RCT for NES indication	Appetite (any time of day)	Case-series signal only	Do not use as substitute for CBT-NES ± sertraline

Special situations

Pre-bariatric evaluation

NES prevalence in bariatric-surgery candidates is 8 to 15 percent (Colles 2007, Runfola 2014). Latner 2004 in Obesity Research is the paper to cite: untreated pre-op NES predicts worse post-surgical weight outcomes at 1 and 2 years. Standard practice is NEDQ or NEQ screening as part of the pre-op behavioral-health evaluation, CBT-NES ± sertraline for a positive screen, and delayed surgery until the pattern is stable. See our bariatric surgery overview for the broader pre-op picture.

Post-bariatric NES

NES can re-emerge post-surgery, often as a “grazing” pattern that circumvents restrictive anatomy. If you notice evening hyperphagia returning in year 1 or 2 after surgery, or nocturnal awakenings to eat that were not present pre-op, request an eating-disorder re-evaluation. Post-op NES is a recognized reason for surgical weight-loss stall or regain.

Comorbid depression

The relationship is bidirectional. Treating NES improves evening mood in most responders; treating depression alone rarely resolves NES. If your NES clinician recommends starting sertraline, that decision is doing double duty — SSRI evidence exists for both NES (Allison 2018) and depression. See depression and weight loss for the wider two-way loop and how to sequence care.

Shift workers

Shift work causes a distinct chrono-appetite problem — circadian misalignment — that looks superficially like NES but is not. Vetter 2013 in Current Opinion in Endocrinology, Diabetes and Obesity reviewed the distinction: shift-worker night eating is a physiological response to an inverted schedule, not a primary eating disorder. Treatment focuses on schedule regularity, strategic light exposure, and meal placement inside the wake window — not sertraline or CBT-NES.

Diabetes and CGM users

Nocturnal hyperglycemia and NES can overlap and worsen each other. If you have type 2 diabetes and a CGM shows repeated overnight glucose excursions coinciding with nocturnal eating, coordinated endocrinology plus eating-disorder care is warranted. Do not adjust basal insulin to “cover” nocturnal eating without a plan — that reinforces the pattern and increases hypoglycemia risk overnight if you sleep through. See continuous glucose monitors for weight loss for the CGM interpretation side.

GLP-1 users

Evening ghrelin blunting on semaglutide or tirzepatide may reduce nocturnal appetite in some patients — that is mechanistically plausible and consistent with small case series. There is no RCT evidence for GLP-1s as a NES treatment as of 2026. Do not treat GLP-1 monotherapy as a substitute for CBT-NES ± sertraline. If you are already on a GLP-1 for weight or diabetes and screen positive for NES, add CBT-NES and consider sertraline; do not remove the eating-disorder specialist from the picture.

Adolescents

NES is rare in adolescents and requires referral to an adolescent eating-disorder specialist. Do not initiate SSRIs in adolescents without pediatric psychiatry involvement — dosing, black-box suicidality warning considerations, and family involvement are different from adult care.

Myths and red flags — what to refute

“Night eating is just bad willpower.” No. NES is a DSM-5-recognized clinical pattern with a measurable circadian phase delay (Goel 2009) and specific evidence-based treatments.
“You just need to lock the kitchen at 8 pm.” Environmental controls help, but they do not resolve the underlying phase-delay and morning-anorexia biology. Locking the kitchen without CBT-NES and a structured breakfast is a durable-failure setup.
“Skipping breakfast is fine if I don’t eat at night.” Skipping breakfast is a driver of NES, not a remedy. The daytime-intake deficit sets up the evening rebound.
“Bariatric surgery will fix NES.” No. Latner 2004 showed pre-op untreated NES worsens post-surgical outcomes, and NES commonly re-emerges post-op as a grazing pattern.
“NES is the same as binge eating.” No. Awareness, control, and quantity criteria differ. BED requires discrete loss-of-control episodes; NES requires a shifted intake curve. The two can co-occur but are separate diagnoses.
“There is no medication for NES.” Sertraline titrated to 200 mg/day has RCT evidence (Allison 2018). It is not curative alone, but it is not “nothing.”

If you are in crisis or having thoughts of self-harm, call or text 988 (Suicide & Crisis Lifeline). For eating-disorder support in the US, the NEDA helpline is 1-800-931-2237. Neither replaces same-day emergency care for imminent risk — call 911 or go to the nearest emergency department.

Bottom line

NES is a real, DSM-5-recognized clinical pattern, and it is treatable. The evidence-based stack is CBT-NES plus sertraline titrated to 200 mg/day, layered on a structured protein-anchored morning meal, sleep hygiene, and morning bright light. Screening with the NEDQ or NEQ is the entry point; diagnosis requires a clinician. Treat NES before bariatric surgery, coordinate care with a mood-disorder clinician when depression is present, and do not accept “just willpower” or “just lock the kitchen” framings — they miss the biology and the treatment. The pattern responds; getting to the right care is the hard part.

Sources

Nora Kim

Medical and surgical weight loss writer